^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
GSK5926371
i
Other names: GSK-5926371, GSK5926371, CMG1A46, 1A46, BR110
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Chimagen Biosci, GSK, Zhejiang Hisun
Drug class:
CD20 inhibitor, CD3 agonist, CD19 inhibitor
Related drugs:
10ms
Phase I/II Clinical Study of 1A46 Drug Substance (clinicaltrials.gov)
P1, N=4, Terminated, BioRay Pharmaceutical Co., Ltd. | N=209 --> 4 | Trial completion date: Apr 2030 --> Nov 2024 | Recruiting --> Terminated | Trial primary completion date: Apr 2030 --> Aug 2024; sponsor's Research and Development strategy adjustment
Enrollment change • Trial completion date • Trial termination • Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
|
GSK5926371
10ms
First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies (clinicaltrials.gov)
P1/2, N=7, Terminated, Chimagen Biosciences, Ltd | N=165 --> 7 | Recruiting --> Terminated; Sponsor's Research and Development strategy adjustment
Enrollment change • Trial termination
|
BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
|
GSK5926371
1year
Phase I/II Clinical Study of 1A46 Drug Substance (clinicaltrials.gov)
P1, N=209, Recruiting, BioRay Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting | Phase classification: P1/2 --> P1
Enrollment open • Phase classification
|
CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
|
CD20 expression • CD19 expression
|
GSK5926371
over2years
Clinical Study of 1A46 Drug Substance (clinicaltrials.gov)
P1/2, N=209, Not yet recruiting, Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd
New P1/2 trial
|
CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
|
CD20 expression • CD19 expression
|
GSK5926371
over3years
First-in-Human (FIH) Trial of 1A46 in Subjects With Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies (clinicaltrials.gov)
P1/2, N=165, Recruiting, Chimagen Biosciences, Ltd | Not yet recruiting --> Recruiting | Initiation date: Apr 2022 --> Jul 2022
Enrollment open • Trial initiation date
|
BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
|
CD20 expression • CD19 expression
|
GSK5926371
over3years
First-in-Human (FIH) Trial of 1A46 in Subjects With Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies (clinicaltrials.gov)
P1/2, N=165, Not yet recruiting, Chimagen Biosciences, Ltd
New P1/2 trial
|
BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
|
CD20 expression • CD19 expression
|
GSK5926371
Share via
